Safety of the BRD9 heterobifunctional degrader CFT8634 in synovial sarcoma and SMARCB1-null tumors: an open-label, dose-escalation, phase 1 clinical trial

Communications Medicine · Published 2026-08-04 · DOI 10.1038/s43856-026-01821-1

Free full text

Authors (17)

Brian A. Van Tine, William D. Tap, Mark Agulnik, Ravin Ratan, Sant P. Chawla, Steven Attia, Anthony Elias, Prabhjot Mundi, Mohammed Milhem, Joseph G. Pressey, Amro Ali, Ingrid Mintautas, Riadh Lobbardi, Huan Liu, Eunju Hurh, Len Reyno, Gregory M. Cote

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tine, B., Tap, W., Agulnik, M., et al. (2026). Safety of the BRD9 heterobifunctional degrader CFT8634 in synovial sarcoma and SMARCB1-null tumors: an open-label, dose-escalation, phase 1 clinical trial. Communications Medicine. https://doi.org/10.1038/s43856-026-01821-1

Related articles

• Evaluation of respiratory disease hospitalisation forecasts using synthetic outbreak data · Communications Medicine · 2026 · Same journal
• OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer · Communications Medicine · 2026 · Same journal
• Site-specific N-glycosylation of alpha-2-macroglobulin reflects the progression of Schistosoma japonicum-induced liver fibrosis · Communications Medicine · 2026 · Same journal
• Quantifying cortical lesions in multiple sclerosis MRI datasets using multi-contrast post-processing and deep learning · Communications Medicine · 2026 · Same journal
• Mapping genetic convergence across brain structure, mental health, and cardiometabolic disease · Communications Medicine · 2026 · Same journal
• Utilising digital contact tracing during a pandemic to measure contact trends by risk group · Communications Medicine · 2026 · Same journal
• Early vitrectomy and intravitreal antibiotics for post-operative exogenous endophthalmitis (EVIAN): a randomised control trial of feasibility · Communications Medicine · 2026 · Same journal
• FGL-1 plasma levels correlate with markers of inflammation and severe disease during SARS-CoV-2 infection · Communications Medicine · 2026 · Same journal
• A meta-learning method with reduced data requirements for training and updating deep learning models on wearable devices · Communications Medicine · 2026 · Same journal
• Birthweight predicts unfavorable adolescent immunometabolic trajectories leading to adult atypical depression in the ALSPAC cohort · Communications Medicine · 2026 · Same journal